77278-93-4

Basic information

• Product Name: 1-(TERT-BUTOXYCARBONYL)-4-((2-PYRIDYL)METHYL)PIPERAZINE
• Synonyms: 1-(TERT-BUTOXYCARBONYL)-4-((2-PYRIDYL)METHYL)PIPERAZINE;TERT-BUTYL-4-((PYRIDIN-2-YL)METHYL)PIPERAZINE-1-CARBOXYLATE
• CAS NO: 77278-93-4
• Molecular Formula: C₁₅H₂₃N₃O₂
• Molecular Weight: 277.36202
• Mol File: 77278-93-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 368.956°C at 760 mmHg
• Flash Point: 176.939°C
• Appearance: /
• Density: 1.122g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.541
• CAS DataBase Reference: 1-(TERT-BUTOXYCARBONYL)-4-((2-PYRIDYL)METHYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(TERT-BUTOXYCARBONYL)-4-((2-PYRIDYL)METHYL)PIPERAZINE(77278-93-4)
• EPA Substance Registry System: 1-(TERT-BUTOXYCARBONYL)-4-((2-PYRIDYL)METHYL)PIPERAZINE(77278-93-4)

Safety Data

• Hazardous Substances Data: 77278-93-4(Hazardous Substances Data)

Usage

General Description

1-(tert-butoxycarbonyl)-4-((2-pyridyl)methyl)piperazine is a chemical compound with a complex structure consisting of a piperazine ring substituted with a tert-butoxycarbonyl group and a 2-pyridylmethyl group. It is commonly used in the synthesis of pharmaceuticals and organic compounds. The tert-butoxycarbonyl group is a protecting group commonly used in organic synthesis to temporarily mask reactive functional groups, while the 2-pyridylmethyl group is a common substituent found in various pharmaceutical compounds. 1-(TERT-BUTOXYCARBONYL)-4-((2-PYRIDYL)METHYL)PIPERAZINE has potential applications in medicinal chemistry and drug development, and its unique structure makes it a valuable building block for the synthesis of new chemical entities.

InChI:InChI=1/C15H23N3O2/c1-15(2,3)20-14(19)18-10-8-17(9-11-18)12-13-6-4-5-7-16-13/h4-7H,8-12H2,1-3H3

Upstream product

• 6959-47-3 2-chloromethylpyridine hydrochloride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 55401-97-3 2-(Bromomethyl)pyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 55579-01-6 1-(pyridine-2-ylmethyl)piperazine 
• 1121-60-4 pyridine-2-carbaldehyde 

Downstream Products

• 1818389-84-2 N-(2-(4-(pyridin-2-ylmethyl)piperazin-1-yl)-5-trifluoromethyl)phenyl-5-(pyridin-4-yl)furan-2-carboxamide 
• 149692-12-6 1-(3-((N-phenoxycarbonyl)amino)-3-phenylpropanoyl)-4-((2-methyl-3-pyridyl)cyanomethyl)piperazine 

Relevant articles and documents

PIPERAZINE DERIVATIVES FOR TREATING DISORDERS

Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.

Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor

A series of 3-aryl-5-acylpiperazinyl-pyrazoles (e.g., 3a-b) initially identified through a high-throughput screening campaign using the aequorin Ca2+ bioluminescence assay as novel, potent small molecule antagonists of the G protein-coupled hum

Synthesis and Structure-Activity Relationships of 1-Acyl-4-(2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF Antagonists

A second generation of (cyanomethyl)piperazines, 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines, with increased oral activity was prepared and evaluated in vitro in PAF-induced platelet aggregation assay (PAG) and in vivo in a PAF-induced hypotension test in normotensive rats (HYP).Oral activity was ascertained through a PAF-induced mortality test in mice (MOR).Attachment of a methyl group at position 2 of our earlier pyridine derivatives resulted in an improvement of 1 order of magnitude or greater in the ID50 of the oral test.Three different types of acylsubstituents of similar potency emerge from this work: N-(diphenylmethylamino)acetyl, 3-substituted 3-hydroxy-3-phenylpropionyl, and N-substituted 3-amino-3-phenylpropionyl groups.The most interesting compounds, 26 (UR-12460, PAG IC50 = 0.040 μM, HYP, ID50 = 0.021 mg/kg iv, MOR, ID50 = 0.30 mg/kg po) and 58 (UR-12519, PAG IC50 = 0.041 μM, HYP, ID50 = 0.015 mg/kg iv, MOR, ID50 = 0.044 mg/kg po), compare favorably with WEB-2086.Compounds 26 and 58 were also tested in active anaphylactic shock (AAS) and endotoxin-induced mortality (EIM) tests.On the basis of these data, compounds 26 and 58 have been selected for further pharmacological development.